Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Author:
- 1 August 2016
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 16 (4) , 238-246
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- The development of endocrine therapy for women with breast cancerCancer Treatment Reviews, 2013
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Research and Treatment, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast CancerCancer Research and Treatment, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJournal of Clinical Oncology, 2009
- Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort StudyAmerican Journal of Epidemiology, 2009
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2008
- Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional AbilityThe Oncologist, 2004